To meet the growing demand, Alleima, a trusted partner of leading medical device manufacturers, will establish a production footprint for its medical business in Asia by opening a new facility in Penang, Malaysia. This operation will further strengthen the company’s precision wire manufacturing capacity to develop life-changing medical solutions with its partners and is expected to be fully operational in 2026.
Alleima’s history goes back decades within the medical segment. The company’s ultra-fine medical wire is used in applications in various fields of medical technology, such as remote patient monitoring, vascular therapy, sensing and neurostimulation, where innovative and high-quality solutions are developed in close collaboration with partners.
Penang, in Malaysia, is a growing Asian hub for medical companies. The new production facility will strengthen the ability to capture growth opportunities in the region by increased capacity and improved manufacturing flexibility. The facility will be governed within the Kanthal Division of Alleima.
“The establishment of a manufacturing footprint will allow us to cater to the increasing demand for our medical products which is growing at a high pace. It will be an important foundation to support our long-term strategy to grow our medical business.” says Robert Stål, President of the Kanthal Division.
“The Asian region is the fastest growing market for medical devices in the world because of its aging population, adoption of advanced medical technologies and other economic growth drivers, so of key strategic importance to our business. The demand is already here, and the new footprint will allow us to better collaborate and serve new and existing customers in the region,” says Gary Davies, President of Business Unit Medical in Kanthal.
Site preparations will start before the end of 2024, with commercial deliveries expected in 2026.
Alleima currently produces medical products in Europe and the US. With the added production footprint in Asia, Alleima will expand its geographical presence and further strengthen deliveries within the strategic medical segment.
